NO20085182L - Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor - Google Patents

Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor

Info

Publication number
NO20085182L
NO20085182L NO20085182A NO20085182A NO20085182L NO 20085182 L NO20085182 L NO 20085182L NO 20085182 A NO20085182 A NO 20085182A NO 20085182 A NO20085182 A NO 20085182A NO 20085182 L NO20085182 L NO 20085182L
Authority
NO
Norway
Prior art keywords
tumors
treatment
antagonists
growth factor
factor receptor
Prior art date
Application number
NO20085182A
Other languages
English (en)
Norwegian (no)
Inventor
Eric Rowinsky
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20085182L publication Critical patent/NO20085182L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20085182A 2006-07-27 2008-12-11 Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor NO20085182L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
PCT/US2007/074448 WO2008014386A2 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Publications (1)

Publication Number Publication Date
NO20085182L true NO20085182L (no) 2009-04-24

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085182A NO20085182L (no) 2006-07-27 2008-12-11 Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor

Country Status (15)

Country Link
EP (1) EP2043688A4 (pt)
JP (1) JP2009544736A (pt)
KR (1) KR20090033841A (pt)
CN (1) CN101484186A (pt)
AU (1) AU2007279261A1 (pt)
BR (1) BRPI0712368A2 (pt)
CA (1) CA2654911A1 (pt)
CR (1) CR10486A (pt)
EA (1) EA200870603A1 (pt)
EC (1) ECSP089011A (pt)
MX (1) MX2008016187A (pt)
NO (1) NO20085182L (pt)
TN (1) TNSN08512A1 (pt)
WO (1) WO2008014386A2 (pt)
ZA (1) ZA200810600B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113853388B (zh) 2019-03-27 2024-07-19 加拿大国家研究委员会 抗-egfrviii抗体及其抗原结合片段

Also Published As

Publication number Publication date
EP2043688A2 (en) 2009-04-08
CA2654911A1 (en) 2008-01-30
BRPI0712368A2 (pt) 2012-06-05
EP2043688A4 (en) 2009-11-11
CN101484186A (zh) 2009-07-15
KR20090033841A (ko) 2009-04-06
AU2007279261A1 (en) 2008-01-31
JP2009544736A (ja) 2009-12-17
TNSN08512A1 (en) 2010-04-14
WO2008014386A2 (en) 2008-01-31
ZA200810600B (en) 2009-11-25
EA200870603A1 (ru) 2009-06-30
CR10486A (es) 2009-02-23
ECSP089011A (es) 2009-01-30
MX2008016187A (es) 2009-01-20
WO2008014386A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
NZ598145A (en) Folate-targeted diagnostics and treatment
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
NO20073651L (no) Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi
SG10201906270VA (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
TN2009000136A1 (en) Sequential combination therapy
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2008025033A3 (en) Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
NZ708802A (en) Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
NO20085182L (no) Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
WO2008002544A3 (en) Unit dosage forms of temozolomide
CY1112203T1 (el) Καινοτομικες θεραπευτικες χρησεις της αδρενεργικης αλφουζοσινης
PL2465519T3 (pl) Leczenie dysfunkcji śródbłonka u pacjentów z cukrzycą
Defina Efficacy of nilotinib in a patient relapse after 9 years of imatinib treatment and in stable complete cytogenetic response
De Castro et al. Treatment beyond progression: What to do when an epidermal growth factor receptor mutant-positive patient progresses to a tyrosine kinase inhibitor?

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application